A highly potent small-molecule inhibitor that stabilizes SHP-2 in its auto-inhibited conformation has been recently developed for treatment of cancers and suggested to be capable of blocking PD-1 coinhibition (Chen et al., 2016). This evidence concerns the gene PTPN11 and cancer.